Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1383&sort=funder
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=funder", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=funder", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1384&sort=funder", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1382&sort=funder" }, "data": [ { "type": "Grant", "id": "11719", "attributes": { "award_id": "1R01AI178009-01", "title": "Long term adverse health outcomes for women and children following SARS-CoV-2 infection during pregnancy", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6243, "first_name": "BROOKE ALLISON", "last_name": "Bozick", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-07-01", "end_date": "2028-06-30", "award_amount": 802700, "principal_investigator": { "id": 11636, "first_name": "Lyndsay Ammon", "last_name": "Avalos", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 769, "ror": "", "name": "KAISER FOUNDATION RESEARCH INSTITUTE", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 8594, "first_name": "Monique Marie", "last_name": "Hedderson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 769, "ror": "", "name": "KAISER FOUNDATION RESEARCH INSTITUTE", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the virus responsible for the global COVID-19 pandemic of unprecedented scale causes a multi-organ disease with widespread effects. Increasing evidence suggests long-term effects of SARS-CoV-2 infection in some individuals present up to a year after initial infection, referred to as Post-Acute Sequelae of SARS-CoV-2 (PASC). Pregnant women and their fetuses may be particularly vulnerable to the long-term effects of SARS-CoV-2 infection. The biological plausibility and emerging epidemiological evidence from SARS-CoV-2 infections in the population highlight the urgent need for research on the long-term effects of SARS-CoV-2 infection during pregnancy on women’s cardiometabolic and neuropsychiatric health outcomes and children’s growth and development. Limitations of current studies of both pregnant women with SARS-CoV-2 infection and their children exposed in utero, include a lack of long-term follow-up, lack of data on pre-existing conditions making it difficult to disentangle risk factors for the infection from its consequences, and limited ability to examine associations by predominant SARS-CoV-2 variant and vaccination status. The proposed study leverages Kaiser Permanente Northern California’s (KPNC’s) high-quality electronic health records (EHR) data on SARS-CoV-2 infection testing and results to assemble a longitudinal pregnancy cohort of >195,000 pregnant women (>22,000 women with SARS-CoV-2 infection during pregnancy and approximately>173,000 without) between March 2020 and December 2022. We will use our robust and comprehensive EHR to follow women and their children for up to 5 years and ascertain clinical diagnoses data. Additionally, we will recruit and survey a subsample of 2000 of the mother-child dyads when the child is 3 years old to ascertain women’s and children’s self/parent-reported subclinical health outcomes not available in the EHR, but that may suggest a need to monitor and/or provide early interventions. We will randomly identify 1000 dyads with SARS-CoV-2 infection during pregnancy (1/3 early variants, 1/3 Delta and 1/3 Omicron variants) and 1000 dyads without SARS-CoV-2 infection during pregnancy. Our study will assess the following: 1) Evaluate the long-term effects of a SARS-CoV-2 infection during pregnancy on women’s cardiometabolic and neuropsychiatric outcomes (EHR and self-report), and 2) Evaluate the long-term effects of in utero exposure to SARS-CoV-2 infection on child growth trajectory and neurodevelopment (EHR and parent-report). We will examine variant, severity of infection and gestational age at infection in relation to all outcomes of interest and explore effect modification by vaccination status, race/ethnicity and pre-existing co-morbidities. Finally, our analyses will include infection status before, during and after pregnancy or birth allowing for estimation of joint effects. This project will fill a significant gap informing women and children exposed to SARS-CoV-2 infection during pregnancy, the public, clinicians, and health care systems of the full spectrum of health consequences of infection.", "keywords": [ "3 year old", "Anxiety", "Biological", "Birth", "Body mass index", "COVID-19", "COVID-19 diagnosis", "COVID-19 impact", "COVID-19 pandemic", "COVID-19 susceptibility", "California", "Cardiac", "Cardiovascular system", "Chest Pain", "Child", "Child Health", "Chronic stress", "Clinical", "Communication", "Data", "Diabetes Mellitus", "Diagnosis", "Disease", "Early Intervention", "Electronic Health Record", "Epidemiology", "Ethnic Origin", "Event", "Exposure to", "Fetus", "Future", "Gestational Age", "Growth", "Growth and Development function", "Health", "Health system", "Healthcare", "Healthcare Systems", "High Risk Woman", "Hospitalization", "Hypertension", "Immune response", "Immunity", "Impairment", "Individual", "Infection", "Joints", "Knowledge", "Long-Term Effects", "Longterm Follow-up", "Mental Depression", "Modification", "Monitor", "Morbidity - disease rate", "Mothers", "Motor", "Neurodevelopmental Impairment", "Neurologic Effect", "Organ", "Outcome", "Parents", "Pathway interactions", "Patient Self-Report", "Persons", "Population", "Post-Acute Sequelae of SARS-CoV-2 Infection", "Post-Traumatic Stress Disorders", "Postpartum Period", "Pregnancy", "Pregnant Women", "Premature Birth", "Problem Solving", "Public Health", "Quality of life", "Race", "Reporting", "Research", "Risk", "Risk Factors", "SARS-CoV-2 B.1.1.7", "SARS-CoV-2 B.1.351", "SARS-CoV-2 B.1.617.2", "SARS-CoV-2 exposure", "SARS-CoV-2 infection", "SARS-CoV-2 infection history", "SARS-CoV-2 positive", "SARS-CoV-2 variant", "Sampling", "Self Assessment", "Severities", "Speech Disorders", "Surveys", "Symptoms", "Testing", "Time", "Vaccination", "Variant", "Virus", "Virus Diseases", "Woman", "cardiometabolism", "clinical diagnosis", "cohort", "comorbidity", "comparison group", "depressive symptoms", "health goals", "high risk", "interest", "long term consequences of COVID-19", "maternal morbidity", "neurodevelopment", "neuropsychiatry", "pandemic disease", "perinatal outcomes", "post SARS-CoV-2 infection", "post pregnancy", "prenatal exposure", "prepregnancy", "recruit", "severe maternal morbidity", "skills", "systemic inflammatory response", "unvaccinated", "venous thromboembolism", "women of color" ], "approved": true } }, { "type": "Grant", "id": "11720", "attributes": { "award_id": "1R24OD035476-01", "title": "Improving Animal Facility Management and Research Quality", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 27589, "first_name": "FLAUBERT", "last_name": "Tchantchou", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-07-01", "end_date": "2024-06-30", "award_amount": 349615, "principal_investigator": { "id": 27590, "first_name": "FRANK J", "last_name": "JENKINS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 848, "ror": "", "name": "UNIVERSITY OF PITTSBURGH AT PITTSBURGH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "ABSTRACT: The University of Pittsburgh Division of Laboratory Animal Resources (DLAR) manages 12 separate facilities in 11 buildings. Our current mouse census is in excess of 33,000 cages. Significant effort is required by husbandry staff for daily cage monitoring including the presence of food and water, bedding condition, and cage and room temperature and humidity. During the COVID-19 pandemic, due to staffing issues, DLAR switched from changing mouse IVC cages every 7 days to every 14 days. The additional 7 days between cage changes caused an increase in labor to monitor food and water levels and the condition of bedding. Caging systems that would improve cage and room monitoring represent much-needed improvement and flexibility to facility management. This grant seeks funding to provide much needed caging by installing Digital Ventilated Caging (DVC) and Leddy Lighting System caging from Tecniplast in three holding rooms. These cages will allow a pilot program to determine their ability to address the issues and concerns described above. This proposed successful pilot program will provide justification for expanding these caging systems throughout the vivaria over time.", "keywords": [ "Address", "Animal Welfare", "Animals", "Beds", "Behavioral", "Breeding", "COVID-19 pandemic", "Censuses", "Circadian Rhythms", "Custom", "Darkness", "Detection", "Experimental Designs", "Faculty", "Food", "Funding", "Goals", "Grant", "Health", "Home", "Housing", "Human", "Human Activities", "Humidity", "Injury", "Laboratory Animal Production and Facilities", "Laboratory Animals", "Light", "Lighting", "Modernization", "Monitor", "Motion", "Movement", "Mus", "Natural regeneration", "Nerve Degeneration", "Noise", "Outcome", "Outcomes Research", "R24", "Reaction Time", "Research", "Research Personnel", "Rodent", "System", "Temperature", "Time", "Transgenic Animals", "Universities", "Water", "animal care", "animal facility", "animal resource", "design", "digital", "field study", "flexibility", "food surveillance", "improved", "innovation", "programs", "success", "ventilation", "vibration" ], "approved": true } }, { "type": "Grant", "id": "11721", "attributes": { "award_id": "1R01HS029460-01", "title": "Rapid learning during a public health emergency: COVID-19 related medication treatment patterns in Medicare", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Agency for Healthcare Research and Quality (AHRQ)" ], "program_reference_codes": [], "program_officials": [ { "id": 22656, "first_name": "Chunliu", "last_name": "Zhan", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-07-01", "end_date": "2027-04-30", "award_amount": 399663, "principal_investigator": { "id": 27591, "first_name": "PINAR", "last_name": "KARACA-MANDIC", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 764, "ror": "https://ror.org/017zqws13", "name": "University of Minnesota", "address": "", "city": "", "state": "MN", "zip": "", "country": "United States", "approved": true }, "abstract": "SUMMARY/ABSTRACT Medical practice is continuously evolving, with substantial resources allocated to developing medical innovations and enhancing clinical evidence on new and existing treatments. In most cases, new evidence supporting approval by the Food and Drug Administration (FDA) demonstrates efficacy of new treatments; after approval, new evidence for existing treatments may show them to be ineffective or unsafe. Understanding whether and how new clinical evidence is integrated into practice is critical from the perspectives of a) improving patient safety and health outcomes; b) addressing racial and socioeconomic equity in access and use; c) designing programs and policies to encourage use of high value, effective treatments and abandon less effective and harmful treatments; d) containing health care costs by allocating limited health care budgets to their most effective use. The COVID-19 pandemic provides a unique opportunity to study the diffusion of evidence into practice by observing adoption and de-adoption behavior of physicians in response to rapidly changing information about potential treatments and risks of continued use of common drugs in the context of COVID-19. This proposal builds on our prior work on de-adoption of harmful or ineffective medical practices by introducing additional factors that could be associated with the rates and timing of adoption and de-adoption of pharmaceutical treatments. We will examine prescription fills and claims-based use of a targeted set of drugs related to COVID-19 using data from Medicare claims for Fee-for-Service (FFS) enrollees. COVID-19 has particularly affected older adults and the disabled and chronically ill, many of whom face increased risk of severe morbidity and mortality from the disease, and potentially from lack of access to medical care during the pandemic. We will investigate how prescribing of COVID-19-related drugs responds to state-level drug policies, FDA safety communications, and COVID-19 pressures on the healthcare system. We will assess how patient characteristics (e.g., race and ethnicity, age, and key comorbidities), as well as physician and medical practice organization characteristics are associated with these prescribing patterns. Three in-depth COVID-19 case studies will assess uptake and de-adoption of treatments associated with lower quality evidence and more rapid turnaround in a context where public attention is closely attuned to every development and pre-print biomedical manuscripts are discussed at length in the popular press. Exploring adoption and de-adoption of treatments in a context of high uncertainty and high burden and prevalence of disease will provide important insights into the role of information quality in physician decision making. In addition, these cases will allow us to explore the effectiveness of state-level regulation of treatments. In particular, hydroxychloroquine was regulated in some states in response to fears that not enough would be available for people using the drug to treat non-COVID-19 conditions.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "11722", "attributes": { "award_id": "1T32TR004417-01", "title": "CTSA Predoctoral T32 at Tufts University", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [ { "id": 22830, "first_name": "Andrew", "last_name": "Louden", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-07-01", "end_date": "2028-06-30", "award_amount": 543495, "principal_investigator": { "id": 27592, "first_name": "DAVID M", "last_name": "KENT", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 863, "ror": "", "name": "TUFTS UNIVERSITY BOSTON", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "We propose to substantially expand opportunities at the Tufts Graduate School of Biomedical Sciences for predoctoral training in clinical and translational science (CTS). Based on our recent experience integrating predoctoral students in our established postdoctoral program, we have found that early exposure to CTS training can profoundly influence the career trajectories of scholars and enrich the learning environment for all levels of trainees. The Tufts CTS Graduate Program, the training core of Tufts Clinical and Translational Science Institute (CTSI), has a long and distinguished history in training leaders in clinical research and CTS. Founded in 1999 as the nation's first clinical research program based at a school of graduate biomedical sciences and an academic medical center, we have continuously evolved to meet the changing needs of CTS training. Now we seek to build on our successful experience to increase our impact preparing the CTS workforce by preparing predoctoral trainees to meet future healthcare challenges. As the world emerges from the COVID-19 pandemic, the case for engaging trainees in CTS research earlier in their careers has never been stronger. While we cannot fully anticipate the specific healthcare challenges that predoctoral trainees will face in the coming decades, we can discern emerging themes that will undoubtedly dominate. For example, it seems certain that future healthcare solutions will increasingly rely on real world evidence emerging from the convergence of machine learning and routinely collected big data. Also, it is abundantly clear from the COVID- 19 pandemic that interactions between humans, animals, and the environment will be a critical, perhaps existential determinant of our health and survival. Finally, while the wealthy appear to be reaching our natural lifespans, durable socioeconomic disparities are estimated to account for roughly one in three premature deaths even in highly developed countries; substantial health gains undoubtedly depend on addressing social determinants of health and other causes of disparity. These concerns, aligned with Tufts' strengths, have shaped our three specialized T32 Program Tracks: Predictive Analytics and Comparative Effectiveness Research (PACER), One Health, and Health Policy and Health Disparities (HPHD). Thus, responding to the call of NCATS to train more predoctoral scholars, we have two principal aims: AIM 1: Inspire and prepare promising professional students as Medical Research Scholars to devote their careers to clinical and translational science. We will provide pathways for professional students (e.g., MD, DVM, DMD, DPT) to augment their clinical education with Certificate, MS, or PhD-level training in CTS. AIM 2: Prepare PhD candidates as Translational Research Scholars to embark on future careers as clinical and translational scientists. We will recruit and train candidates with prior biomedical backgrounds into our CTS PhD program; and provide pathways for doctoral students in related fields (e.g., basic science, computer science, nutrition) to augment their research training with Certificate or MS-level training in CTS.", "keywords": [ "Universities", "pre-doctoral" ], "approved": true } }, { "type": "Grant", "id": "11723", "attributes": { "award_id": "1R36HS029568-01", "title": "Unraveling Crisis Text Services: Perceptions and Experiences among Low-income Young Adults with Suicidal Ideation", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Agency for Healthcare Research and Quality (AHRQ)" ], "program_reference_codes": [], "program_officials": [ { "id": 26941, "first_name": "Christopher M", "last_name": "Gaines", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-07-01", "end_date": "2024-11-30", "award_amount": 42806, "principal_investigator": { "id": 27593, "first_name": "KATE", "last_name": "LAFORGE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 768, "ror": "https://ror.org/043mz5j54", "name": "University of California, San Francisco", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Suicide was the third leading cause of death for young adults aged 15-24 in 2021. Young adults experienced increased suicidal ideation during the COVID-19 pandemic and are at an elevated risk for suicidal ideation and suicide attempts. Health systems have struggled to meet the mental health needs of young adults. Crisis text services are free, anonymous, and rapidly accessible resources that can provide critical mental health resources for low-income young adults. In 2020, the largest crisis text service organization engaged in conversations with 844,000 texters, 30% aged 18-24. In July 2022, the federal government established the 988 national suicide crisis line (which connects users to the National Suicide Prevention Lifeline) and volume rose 45% in the first week of service, demonstrating the high demand for crisis text service. Crisis text services can be accessed by young people with low financial resources who may not access care because of rurality, cost, or lack of insurance coverage for mental healthcare. Crisis text services can link to primary care for people who otherwise do not have access to health services and constitute a free resource that clinicians can recommend to patients. Despite the widespread use of crisis text services, little is known about perceptions and experiences using crisis text services among young adults. A better understanding of how young adults use or choose not to use crisis text services during a mental health crisis could improve the effectiveness of crisis text services. This project will use sequential explanatory mixed methods to address two specific aims: Aim 1 Describe low-income young adults' help-seeking behaviors, motivations, barriers to use, and impact of crisis text services for suicidal ideation through a web-based survey with 100-125 low- income young adults who have experienced SI in the past six months. Participants will be recruited using social media. Quantitative close-ended survey items will be analyzed descriptively, describing differences between young adults who engaged with crisis text services and those who did not. Qualitative open-ended survey items will be analyzed using thematic analysis and used to direct the focus of Aim 2 interviews. Aim 2 Explore perceptions of and experiences with crisis text services among low-income young adults with suicidal ideation via in-depth interviewing with adults aged 18-24. The sample will include those who engaged with a crisis text service for suicidal ideation (n=20) and those who did not engage with a crisis text service when experiencing suicidal ideation (n=20). Participants will be recruited via social media, healthcare providers, and local organizations and interviewed via synchronous text, phone, or videoconference. Data will be analyzed using grounded theory. This research will support health service improvements for AHRQ priority populations, including adolescents and those who are low-income and rural. Findings from this study can be used to inform suicide prevention interventions, crisis text service refinement, and as pilot data for future crisis text service research.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "11724", "attributes": { "award_id": "1K99DK133502-01A1", "title": "Mechanisms of mitochondrial-ER communication during dietary and thermal induced stress", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)" ], "program_reference_codes": [], "program_officials": [ { "id": 23797, "first_name": "CAROL R", "last_name": "HAFT", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-07-01", "end_date": "2025-06-30", "award_amount": 90000, "principal_investigator": { "id": 27594, "first_name": "Pedro Antonio", "last_name": "Latorre Muro", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 997, "ror": "", "name": "DANA-FARBER CANCER INST", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "Obesity is a pandemic affecting 40% of the population that increases the risk of serious metabolic diseases including type 2 diabetes and severe forms of SARS-CoV2 infection. Obesity reduces insulin sensitivity and dysregulates glucose homeostasis sustaining high blood glucose levels and the development of type 2 diabetes. Activation of brown adipocytes (BAs) is a promising approach to treat obesity and associated diseases. Brown adipocytes rely on an extensive network of mitochondria that increases energy expenditure and maintains glucose homeostasis through glucose, amino acid, and fatty acid oxidation. During fat-induced stress, mitochondrial-endoplasmic reticulum (ER) communication sustains cellular function in BAs. However, the mechanisms by which mitochondrial-ER communication shapes cellular adaptation during obesity are poorly understood. Therefore, studying these pathways will provide new therapeutical approaches to target obesity. The main goal of this application is to study the mechanisms of mitochondrial-ER communication that ensure mitochondrial function and cellular homeostasis during diet-induced stress. We have described that in BAs mitochondrial-ER communication promotes thermogenesis during cold stimulation through the ER-resident kinase PERK. To follow up this work, in Aim 1, the effects of long-term high fat diet (HFD) will be studied in UCP1-Cre PERK-/- mice exposed to different dietary and bioenergetic conditions. Our preliminary information suggests that PERK may be signaling to the chaperone PPID to control mitochondrial protein import. In Aim 2, structural approaches using Cryogenic Electron Microscopy (CryoEM) will be used to explore the molecular interactions that control and maintain mitochondrial functions in BAs including mitochondrial protein import, focusing on PPID-dependent pathway, and cellular respiration during dietary and thermal stress. Finally, in Aim 3 the role of PPID in physiology and cellular functions will be studied in mice exposed to diet and thermal stress. While Aims 1 and part of 2 will be completed during the training stage, part of Aim 2 and the entire Aim 3 will be conducted during the independent phase of the award. The extensive training in different fields proposed in this application including physiology and cellular and structural biology will provide the tools to become an independent researcher and study the mechanisms of inter- organalle communication that regulate mitochondrial biogenesis and cellular metabolism. This training will be received in the vibrant scientific communities of Dana-Farber Cancer Institute and Harvard Medical School. This environment will expose me to the collaborations and discussions necessary for career development and future opportunities. Dr. Puigserver mentorship will be supportive to establish those connections and actively guide me in talk and manuscript preparation, student mentorship, experimental design, and career development. Together, the research and career development plans proposed in this application will strengthen my skills and competitiveness to become an independent researcher at a major institution.", "keywords": [ "Adipocytes", "Adipose tissue", "Adrenergic Agents", "Adrenergic Receptor", "Affect", "Amino Acids", "Award", "Binding", "Biochemical", "Bioenergetics", "Biogenesis", "Blood Glucose", "Body Weight", "CRISPR/Cas technology", "Cardiovascular Diseases", "Cell Respiration", "Cell physiology", "Cellular biology", "Client", "Collaborations", "Communication", "Communities", "Complex", "Country", "Crista ampullaris", "Cryoelectron Microscopy", "Dana-Farber Cancer Institute", "Data", "Development", "Development Plans", "Diabetes Mellitus", "Diet", "Disease", "Endoplasmic Reticulum", "Energy Metabolism", "Ensure", "Environment", "Epidemic", "Equilibrium", "Event", "Exercise", "Experimental Designs", "Exposure to", "Fatty Acids", "Fatty Liver", "Fatty acid glycerol esters", "Future", "Glucose", "Goals", "Health", "Heat-Shock Proteins 70", "Heat-Shock Proteins 90", "High Fat Diet", "Homeostasis", "In Vitro", "Individual", "Inflammation", "Institution", "Insulin Resistance", "Knockout Mice", "Knowledge", "Laboratories", "Liver", "Long-Term Effects", "LoxP-flanked allele", "Malignant Neoplasms", "Manuscripts", "Mass Spectrum Analysis", "Membrane", "Mentorship", "Metabolic Diseases", "Metabolism", "Microscope", "Mitochondria", "Mitochondrial Proteins", "Modeling", "Molecular", "Molecular Chaperones", "Monitor", "Mus", "Non-Insulin-Dependent Diabetes Mellitus", "Norepinephrine", "Nuclear Proteins", "Obesity", "Organ", "Organelles", "Outcome", "PERK kinase", "Pathway interactions", "Phase", "Physiology", "Population", "Preparation", "Protein Import", "Protein Precursors", "Receptor Signaling", "Regulation", "Regulatory Element", "Research", "Research Personnel", "Risk", "Role", "SARS-CoV-2 infection", "Sampling", "Shapes", "Signal Pathway", "Signal Transduction", "Skeletal Muscle", "Stress", "Students", "Thermogenesis", "Training", "Weight Gain", "Work", "acid stress", "age related", "blood glucose regulation", "bone", "career development", "diet-induced obesity", "dietary", "dietary control", "energy balance", "fatty acid oxidation", "follow-up", "improved", "in vivo", "insulin sensitivity", "medical schools", "mouse model", "novel", "novel therapeutic intervention", "pandemic disease", "protein complex", "protein function", "research and development", "response", "skills", "stressor", "structural biology", "sugar", "therapeutic target", "thermal stress", "tool" ], "approved": true } }, { "type": "Grant", "id": "11725", "attributes": { "award_id": "1P30GM145500-01A1", "title": "Lentivirus Construct Core", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2023-07-01", "end_date": "2028-06-30", "award_amount": 213200, "principal_investigator": { "id": 27595, "first_name": "OLIN D.", "last_name": "Liang", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1416, "ror": "https://ror.org/01aw9fv09", "name": "Rhode Island Hospital", "address": "", "city": "", "state": "RI", "zip": "", "country": "United States", "approved": true }, "abstract": "Project Summary/Abstract: The past 20 years have seen a rapid expansion in the use of viral gene transfer vectors, with approved therapies and late stage clinical trials underway for the treatment of genetic disorders and multiple forms of cancer, as well as prevention of infectious diseases through vaccination. Major innovations in vector design and virus production have been accomplished for the three most widely used viral vector systems based on adenovirus, adeno- associated virus (AAV), and lentivirus. For laboratory investigators, cell and molecular biology methods to stably over-express and knockout a gene in cells and tissues have become indispensable in modern biomedical research. Lentivirus-mediated over-expression and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) knockout techniques are particularly powerful due to their efficiency and the capability of infecting dividing and non-dividing cells. Given the significant need and demand to use these viral gene transfer technologies and the lack of expert service providers in Rhode Island and the rest Southern New England region, we propose a Lentivirus Construct Core for the Stem Cells and Aging (SCA) COBRE Phase 3. Our long-term goal is to provide cutting-edge viral gene transfer technologies to the greater biomedical research community in Rhode Island and beyond. To accomplish this goal, we propose the following 4 Specific Aims: Specific Aim 1. To provide lentivirus technologies for easy access and efficient use. Specific Aim 2. To enhance the competitiveness of Rhode Island investigators to secure federal research funding. Specific Aim 3. To align our Core with translational research. Specific Aim 4. To become an independent self-sustainable service research facility. Innovations and impact: Recombinant viral vectors are powerful gene delivery tools for cells, animal models, and clinical applications. The lentiviral constructs from our Core will differ in their suitability for different applications, and will allow investigators to monitor cell functions, replace, correct, express or block expression of target genes, tag cells for fate determination, and change the physiological state of specific cell populations. The timely development of COVID-19 pseudovirus variants by our Core was a prime example of innovation. To genetically engineer oncolytic adenovirus encoding bispecific T cell engagers is cutting-edge, and the novel immunovirotherapies have the potential to make a profound impact in cancer treatments. The current exponential growth of clinical trials using AAV vectors suggests that we are only at the beginning of what is achievable for AAV as the leading platform for gene therapies. These innovations can potentially address diseases that have no other treatment options. In this vein, the Lentivirus Construct Core has already successfully made and will continue to make a positive impact as a catalyst on basic and translational research to improve human health.", "keywords": [ "2019-nCoV", "Address", "Adenoviruses", "Adoption", "Aging", "Animal Model", "Basic Science", "Biology", "Biomedical Research", "COVID-19", "COVID-19 pandemic", "Caliber", "Cancer Center", "Cardiovascular system", "Cell physiology", "Cells", "Cellular biology", "Centers of Research Excellence", "Clinical Trials", "Clustered Regularly Interspaced Short Palindromic Repeats", "Collaborations", "Communicable Diseases", "Communities", "Country", "Data", "Dependovirus", "Development", "Disease", "Faculty", "Fees", "Funding", "Gene Delivery", "Gene Transduction Agent", "Genes", "Genetic Diseases", "Genetic Engineering", "Goals", "Grant", "Growth", "Health", "Health Services Research", "Hematologic Neoplasms", "Hospitals", "Human", "Infrastructure", "Institution", "Interphase Cell", "K-Series Research Career Programs", "Knock-out", "Laboratories", "Lentivirus", "Malignant Neoplasms", "Mediating", "Medical center", "Methods", "Modernization", "Molecular Biology", "Monitor", "Neurosciences", "New England", "Orthopedics", "Pathogenesis", "Phase", "Physicians", "Physiological", "Population", "Prevention", "Production", "Research", "Research Activity", "Research Personnel", "Rest", "Rhode Island", "Role", "Scientist", "Secure", "Series", "Services", "Solid Neoplasm", "Strategic Planning", "System", "Techniques", "Technology", "Technology Transfer", "Tissues", "Translational Research", "United States National Institutes of Health", "Universities", "Vaccination", "Variant", "Veins", "Viral", "Viral Genes", "Viral Vector", "Virus", "adeno-associated viral vector", "bi-specific T cell engager", "cancer therapy", "catalyst", "clinical application", "cost", "design", "diagnostic tool", "experimental study", "gene therapy", "gene transfer vector", "immunotherapeutic virotherapy", "improved", "innovation", "interest", "laboratory equipment", "medical schools", "meetings", "member", "novel", "novel diagnostics", "novel therapeutics", "oncolytic adenovirus", "overexpression", "recombinant viral vector", "research facility", "service providers", "sound", "stem cells", "tool", "translational research program", "vector" ], "approved": true } }, { "type": "Grant", "id": "11726", "attributes": { "award_id": "1U18FD008035-01", "title": "Increasing SARS-CoV-2 (COVID-19) testing capacity at the Nebraska Veterinary Diagnostic Center", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 26272, "first_name": "Megan", "last_name": "Miller", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-07-01", "end_date": "2024-06-30", "award_amount": 87793, "principal_investigator": { "id": 27596, "first_name": "John Dustin", "last_name": "Loy", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 978, "ror": "", "name": "UNIVERSITY OF NEBRASKA LINCOLN", "address": "", "city": "", "state": "NE", "zip": "", "country": "United States", "approved": true }, "abstract": "The Nebraska Veterinary Diagnostic Center (NVDC) is a full-service veterinary diagnostic laboratory, is fully accredited by the American Association of Veterinary Laboratory Diagnosticians, is a member of FDA-CVM Vet-LIRN network, is a National Animal Health Laboratory Network (NAHLN) Level 1 laboratory, and is a certificated laboratory for National Poultry Improvement Plan testing. The laboratory processes over 300,000 specimens annually from a variety of species including livestock, companion animals, poultry, wildlife, and zoo animals. As part of a collaborative effort to enhance surveillance for SARS-CoV-2 in animals, more than 3,600 animals diverse animal species were tested in 2022-2023. To increase the diagnostics testing capacity and capabilities for SARS-CoV-2 in animals, the NVDC is seeking funds to purchase a digital PCR system. This equipment will enable the NVDC to enhance SARS-CoV-2 diagnostic testing by allowing extremely sensitive detection of SARS-CoV-2 in animal specimens. Additionally, the digital PCR approaches allows for quantification of SAR- CoV-2 genomes in clinical samples, which will help inform clinicians and One Health partners in assessing virus levels and transmission in animals.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "11727", "attributes": { "award_id": "2I01CX002219-05A2", "title": "Inflammation Resolving Lipid Mediators: Novel Therapy for Alcohol AssociatedLiver Disease", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2023-07-01", "end_date": "2027-06-30", "award_amount": null, "principal_investigator": { "id": 27597, "first_name": "CRAIG J.", "last_name": "MCCLAIN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2042, "ror": "", "name": "LOUISVILLE VA MEDICAL MEDICAL CENTER", "address": "", "city": "", "state": "KY", "zip": "", "country": "United States", "approved": true }, "abstract": "Alcohol-associated liver disease (ALD) is a major health problem in the US (especially in the Veteran population) and alcohol abuse/ALD has increased dramatically during the COVID pandemic. In spite of the magnitude of this problem, there is no FDA-approved therapy for any stage of ALD. In addition, the mechanisms and regulators of disease progression and severity are incompletely understood. Dietary fats play an important interactive role with alcohol consumption in ALD pathogenesis, however, the role of specific n3 polyunsaturated fatty acids (PUFAs) in ALD are not well defined. Our central hypothesis is that n3 PUFAs are beneficial in ALD, in part, via n3-PUFA-derived pro-resolving mediators, which facilitate inflammation resolution, improvement in the gut-liver axis, and subsequent attenuation of liver injury. We propose that n3 PUFA- derived resolvin D1 (RvD1) is a potential therapeutic agent in ALD acting via RvD1-FPR2-NEAT1 signaling to suppress pro-inflammatory cytokines and to promote repair of hepatocellular damage, in part, via enhancement of pro-restorative macrophages. We postulate that compromised inflammation resolution due to impaired RvD1 production/signaling is a critical nutritional factor contributing to the progression and severity of ALD/alcohol- associated hepatitis (AH) in humans. The Specific Aims of the proposal are: Aim 1: determine the role and molecular mechanism(s) underlying n3 PUFA and RvD1 beneficial effects in EtOH-induced liver injury and resolution of inflammation associated with ALD. We will determine whether beneficial effects occur through an increase in n3-PUFA-derived specialized pro-resolving mediators (SPMs), and RvD1-FPR2 and Neat1-mediated suppression of pro-inflammatory cytokine signaling and reprogramming pro-inflammatory macrophages to a pro- restorative phenotype. Wild Type (WT), Fpr2-/-, Neat1-/-, and transgenic fat-1 mice (which are able to endogenously convert n6 to n3 PUFAs) will be used in this Aim. Aim 2: examine the role n3-PUFAs and RvD1 in maintaining gut barrier integrity, and in the resolution of intestinal inflammation in experimental ALD. We will: i) test in vivo, in animal models, and in vitro, in intestinal organoid culture, whether n3 PUFAs or RvD1 improve intestinal barrier damage by attenuating intestinal immune dysregulation; ii) test in vivo whether disruption of the RvD1-FPR2 axis exacerbates, while blocking Neat1 signaling attenuates, intestinal inflammation and alterations in the gut barrier integrity; and iii) determine the contribution of the gut microbiota to the beneficial effects of n3 PUFAs and RvD1 in experimental ALD. Aim 3: translate and extend our findings in animal models to human ALD. Utilizing human samples obtained from Veteran AH patients, we will: i) examine plasma SPM levels and correlate plasma SPM levels with markers of liver injury, systemic inflammation, and intestinal permeability; ii) evaluate basal and LPS-inducible SPM production in whole blood (ex-vivo system) and blood monocytes; and iii) test whether RvD1 improves the phagocytosis/efferocytosis capacity of blood monocytes, and determine if disruption of the RvD1-FPR2 axis will enhance, while silencing of NEAT1 will decrease, pro-inflammatory cytokine expression in human monocytes. These three aims will define both untested novel mechanisms for ALD initiation/progression as well as potential novel therapy that could be rapidly initiated for Veterans with ALD.", "keywords": [ "Alcohol abuse", "Alcohol consumption", "Alcoholic Hepatitis", "Alcoholic Liver Diseases", "Alcoholic beverage heavy drinker", "Alcohols", "Animal Model", "Arachidonate 15-Lipoxygenase", "Attenuated", "Biological Response Modifiers", "Breast", "COVID-19 pandemic", "Cessation of life", "Chronic", "Cirrhosis", "Clinical", "Colon", "Cytokine Signaling", "Data", "Diet", "Dietary Fats", "Dietary Intervention", "Disease", "Disease Progression", "Down-Regulation", "Epidemic", "Ethanol", "Experimental Animal Model", "FAT gene", "FDA approved", "FPR2 gene", "Future", "GPR32 gene", "Health", "Health Care Costs", "Hepatic", "Hepatitis", "Hepatitis C", "Hepatocellular Damage", "Homeostasis", "Host Defense", "Human", "Immune", "Immune response", "Immunity", "Impairment", "In Vitro", "Individual", "Inflammation", "Inflammatory", "Intestinal permeability", "Intestines", "Linoleic Acids", "Liver diseases", "Mediating", "Mediator", "Modeling", "Molecular", "Mus", "Nuclear", "Nutritional", "Organoids", "PTGS2 gene", "Pathogenesis", "Pathway interactions", "Patients", "Phagocytosis", "Phenotype", "Plasma", "Play", "Polyunsaturated Fatty Acids", "Production", "Prognosis", "Prostate", "Research", "Resolution", "Rodent", "Role", "Sampling", "Severities", "Severity of illness", "Signal Transduction", "Survivors", "System", "Testing", "Therapeutic Agents", "Time", "Tissues", "Transcript", "Transgenic Organisms", "Translating", "United States Department of Veterans Affairs", "Untranslated RNA", "Veterans", "Whole Blood", "attenuation", "cancer type", "cyclooxygenase 1", "cytokine", "gut inflammation", "gut microbiota", "gut-liver axis", "improved", "in vivo evaluation", "intestinal barrier", "intestinal injury", "lipid mediator", "liver inflammation", "liver injury", "macrophage", "military veteran", "monocyte", "mortality", "new therapeutic target", "novel", "novel therapeutics", "preclinical study", "receptor", "repaired", "systemic inflammatory response", "tissue repair" ], "approved": true } }, { "type": "Grant", "id": "11728", "attributes": { "award_id": "1F32HL167551-01", "title": "Physiologic Predictors of Respiratory Failure in Patients Presenting with Dyspnea", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 20693, "first_name": "Roya", "last_name": "Kalantari", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-07-01", "end_date": "2025-06-30", "award_amount": 83304, "principal_investigator": { "id": 27598, "first_name": "William Cameron", "last_name": "McGuire", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 760, "ror": "https://ror.org/0168r3w48", "name": "University of California, San Diego", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Presentations of respiratory failure can vary from mild requiring supplemental oxygen to more severe requiring invasive mechanical ventilation (i.e., acute respiratory distress syndrome or ARDS). Early in respiratory failure patients often have abnormalities in gas exchange, control of breathing, and/or pulmonary mechanics. During the ongoing COVID-19 pandemic, some studies have demonstrated that increased respiratory drive is associated with worse clinical outcomes while others have demonstrated contrary findings. We have also demonstrated that a noninvasive assessment of gas exchange using the alveolar gas meter (AGM) is predictive of who will require supplemental oxygen from COVID-19 infection. Additional studies predating the COVID-19 pandemic showed that increased inspiratory effort, large transpulmonary pressure changes, and elevated dead space were all associated with worse outcomes in ARDS. However, many of these studies focused on patients already intubated and mechanically ventilated. Less is known about the relevance of these parameters in spontaneously breathing individuals. For a few years now the notion of patient self-inflicted lung injury (P-SILI) has been gaining traction in the medical literature. The basic concept is that patients with impending respiratory failure from existing lung injury can cause worsening damage to their lungs. If patients are spontaneously breathing with excessively high respiratory drive, then they may generate excessively negative inspiratory efforts leading to major transpulmonary pressure changes. The results of these abnormalities are large tidal volumes like mechanically ventilating someone with injurious tidal volumes prior to the advent of low tidal volume ventilation (LTVV). Also, retrospective review of large cohort studies and randomized controlled trials of ARDS patients have demonstrated that spontaneously breathing patients prior to intubation often generated excessively large tidal volumes. Whether their subsequent lung injury was entirely due to their underlying ARDS pathology or partially due to superimposed P-SILI is not known. If a physiological signature of impending respiratory failure in spontaneously breathing individuals exists and it is associated with elevated respiratory drive, steps can subsequently be taken to mitigate the increased drive and study the longitudinal effects of these variables in patients who develop respiratory failure. Moreover, if such a signature exists and intervention abrogates some of the subsequent lung injury, this is a strong proof of concept for P-SILI in vivo. We aim to test three independent but related hypotheses. First, the AGM is a novel and simple technique which can be used to identify patients at increased risk for respiratory failure better than traditional metrics. Second, the breath hold maneuver is a validated technique to assess control of breathing that can identify patients with poor respiratory prognosis. Third, the airway occlusion pressure will provide additional predictive value in identifying high risk patients. This proposal will lay the groundwork for the PI to gain experience and training for a long and productive academic medical career.", "keywords": [ "Accident and Emergency department", "Acute Respiratory Distress Syndrome", "Address", "Air", "Alveolar", "Animal Experiments", "Brain", "Breathing", "COVID-19 pandemic", "COVID-19 patient", "Cannulas", "Clinical", "Cohort Studies", "Critical Illness", "Data", "Deterioration", "Devices", "Dyspnea", "Equipment", "Gases", "Hospitalization", "Impairment", "Individual", "Injections", "Intervention", "Intubation", "Laboratories", "Life Support Systems", "Literature", "Longitudinal Studies", "Lung", "Lung diseases", "Measurement", "Mechanical ventilation", "Mechanics", "Medical", "Nose", "Outcome", "Oxygen", "Oxygen Therapy Care", "Pathogenesis", "Pathology", "Patient Triage", "Patients", "Physiological", "Physiology", "Predictive Value", "Probability", "Productivity", "Prognosis", "Randomized Controlled Trials", "Research Design", "Respiratory Failure", "Respiratory Muscles", "Respiratory physiology", "Risk", "SARS-CoV-2 infection", "Salicylic Acids", "Shortness of Breath", "Stress", "Structure of parenchyma of lung", "Symptoms", "Techniques", "Testing", "Therapeutic", "Tidal Volume", "Traction", "Training", "Vaccines", "Viral Respiratory Tract Infection", "career", "cisterna magna", "cohort", "experience", "high risk", "human data", "in vivo", "lung injury", "lung pressure", "meter", "millisecond", "murine nodule inducing virus", "novel", "pandemic disease", "point of care testing", "pressure", "prevent", "prognostication", "respiratory", "supplemental oxygen", "theories", "tool", "ventilation" ], "approved": true } } ], "meta": { "pagination": { "page": 1383, "pages": 1424, "count": 14236 } } }